Keywords such as “episodic migraine,” “efficacy,” “erenumab,” “preventive treatment,” “safety,” “placebo,” “galcanezumab,” “ubrogepant,” and “rimegepant” signify areas of emphasis and potential growth in CGRP-related migraine research. Here, CALCA is linked to migraine disorder.